Metabolic signatures of cancer cells and stem cells.
Journal
Nature metabolism
ISSN: 2522-5812
Titre abrégé: Nat Metab
Pays: Germany
ID NLM: 101736592
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
entrez:
28
6
2019
pubmed:
28
6
2019
medline:
28
6
2019
Statut:
ppublish
Résumé
In contrast to terminally differentiated cells, cancer cells and stem cells retain the ability to re-enter the cell cycle and proliferate. In order to proliferate, cells must increase the uptake and catabolism of nutrients to support anabolic cell growth. Intermediates of central metabolic pathways have emerged as key players that can influence cell differentiation 'decisions', processes relevant for both oncogenesis and normal development. Consequently, how cells rewire metabolic pathways to support proliferation may have profound consequences for cellular identity. Here, we discuss the metabolic programs that support proliferation and explore how metabolic states are intimately entwined with the cell fate decisions that characterize stem cells and cancer cells. By comparing the metabolism of pluripotent stem cells and cancer cells, we hope to illuminate common metabolic strategies as well as distinct metabolic features that may represent specialized adaptations to unique cellular demands.
Identifiants
pubmed: 31245788
doi: 10.1038/s42255-019-0032-0
pmc: PMC6594714
mid: NIHMS1036775
pii: 10.1038/s42255-019-0032-0
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Pagination
177-188Subventions
Organisme : NCI NIH HHS
ID : K08 CA201483
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Déclaration de conflit d'intérêts
Competing Interests. A.I. has previously consulted for Foundation Medicine, Inc.
Références
Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009).
doi: 10.1126/science.1160809
Beaudin, A. E. & Stover, P. J. Insights into metabolic mechanisms underlying folate-responsive neural tube defects: a minireview. Birth Defects Res. A. Clin. Mol. Teratol. 85, 274–284 (2009).
pubmed: 19180567
pmcid: 4435943
doi: 10.1002/bdra.20553
Luengo, A., Gui, D. Y. & Vander Heiden, M. G. Targeting metabolism for cancer therapy. Cell Chem. Biol. 24, 1161–1180 (2017).
pubmed: 28938091
pmcid: 5744685
doi: 10.1016/j.chembiol.2017.08.028
Kong, H. & Chandel, N. S. Regulation of redox balance in cancer and T cells. J. Biol. Chem. 293, 7499–7507 (2018).
pubmed: 29282291
doi: 10.1074/jbc.TM117.000257
Chantranupong, L., Wolfson, R. L. & Sabatini, D. M. Nutrient-sensing mechanisms across evolution. Cell 161, 67–83 (2015).
pubmed: 25815986
pmcid: 4384161
doi: 10.1016/j.cell.2015.02.041
Schvartzman, J. M., Thompson, C. B. & Finley, L. W. S. Metabolic regulation of chromatin modifications and gene expression. J. Cell Biol. 217, 2247–2259 (2018).
pubmed: 29760106
pmcid: 6028552
doi: 10.1083/jcb.201803061
Weinberger, L., Ayyash, M., Novershtern, N. & Hanna, J. H. Dynamic stem cell states: naive to primed pluripotency in rodents and humans. Nat. Rev. Mol. Cell Biol. 17, 155–169 (2016).
pubmed: 26860365
doi: 10.1038/nrm.2015.28
Martello, G. & Smith, A. The nature of embryonic stem cells. Annu. Rev. Cell Dev. Biol. 30, 647–675 (2014).
pubmed: 25288119
doi: 10.1146/annurev-cellbio-100913-013116
Fan, J. et al. Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol. Syst. Biol. 9, 712 (2013).
pubmed: 24301801
pmcid: 3882799
doi: 10.1038/msb.2013.65
Hosios, A. M. et al. Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells. Dev. Cell 36, 540–549 (2016).
pubmed: 26954548
pmcid: 4766004
doi: 10.1016/j.devcel.2016.02.012
Pavlova, N. N. & Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell Metab. 23, 27–47 (2016).
pubmed: 26771115
pmcid: 4715268
doi: 10.1016/j.cmet.2015.12.006
DeBerardinis, R. J. & Chandel, N. S. Fundamentals of cancer metabolism. Sci. Adv. 2, e1600200 (2016).
pubmed: 27386546
pmcid: 4928883
doi: 10.1126/sciadv.1600200
Vander Heiden, M. G. & DeBerardinis, R. J. Understanding the intersections between metabolism and cancer biology. Cell 168, 657–669 (2017).
pmcid: 5329766
doi: 10.1016/j.cell.2016.12.039
Carey, B. W., Finley, L. W., Cross, J. R., Allis, C. D. & Thompson, C. B. Intracellular α-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 518, 413–416 (2015).
pubmed: 25487152
doi: 10.1038/nature13981
Tohyama, S. et al. Glutamine oxidation is indispensable for survival of human pluripotent stem cells. Cell Metab. 23, 663–674 (2016).
pubmed: 27050306
doi: 10.1016/j.cmet.2016.03.001
Boroughs, L. K. & DeBerardinis, R. J. Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 17, 351–359 (2015).
pubmed: 25774832
pmcid: 4939711
doi: 10.1038/ncb3124
Chung, S. et al. Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem cells. Nat. Clin. Pract. Cardiovasc. Med. 4(Suppl. 1), S60–S67 (2007).
pubmed: 17230217
pmcid: 3232050
doi: 10.1038/ncpcardio0766
Zhou, W. et al. HIF1α induced switch from bivalent to exclusively glycolytic metabolism during ESC-to-EpiSC/hESC transition. EMBO J. 31, 2103–2116 (2012).
pubmed: 22446391
pmcid: 3343469
doi: 10.1038/emboj.2012.71
Zhang, J. et al. UCP2 regulates energy metabolism and differentiation potential of human pluripotent stem cells. EMBO J. 30, 4860–4873 (2011).
pubmed: 22085932
pmcid: 3243621
doi: 10.1038/emboj.2011.401
Gu, W. et al. Glycolytic metabolism plays a functional role in regulating human pluripotent stem cell state. Cell Stem Cell 19, 476–490 (2016).
pubmed: 27618217
pmcid: 5055460
doi: 10.1016/j.stem.2016.08.008
Moussaieff, A. et al. Glycolysis-mediated changes in acetyl-CoA and histone acetylation control the early differentiation of embryonic stem cells. Cell Metab. 21, 392–402 (2015).
pubmed: 25738455
doi: 10.1016/j.cmet.2015.02.002
Cliff, T. S. et al. MYC controls human pluripotent stem cell fate decisions through regulation of metabolic flux. Cell Stem Cell 21, 502–516 (2017).
pubmed: 28965765
pmcid: 5644510
doi: 10.1016/j.stem.2017.08.018
Folmes, C. D. et al. Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. Cell Metab. 14, 264–271 (2011).
pubmed: 21803296
pmcid: 3156138
doi: 10.1016/j.cmet.2011.06.011
Panopoulos, A. D. et al. The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming. Cell Res. 22, 168–177 (2012).
pubmed: 22064701
doi: 10.1038/cr.2011.177
Mathieu, J. et al. Hypoxia-inducible factors have distinct and stage-specific roles during reprogramming of human cells to pluripotency. Cell Stem Cell 14, 592–605 (2014).
pubmed: 24656769
pmcid: 4028142
doi: 10.1016/j.stem.2014.02.012
Kim, H. et al. Core pluripotency factors directly regulate metabolism in embryonic stem cell to maintain pluripotency. Stem Cells 33, 2699–2711 (2015).
pubmed: 26059508
doi: 10.1002/stem.2073
Liberti, M. V. & Locasale, J. W. The Warburg effect: how does it benefit cancer cells? Trends Biochem. Sci. 41, 211–218 (2016).
pubmed: 26778478
pmcid: 4783224
doi: 10.1016/j.tibs.2015.12.001
Prigione, A., Fauler, B., Lurz, R., Lehrach, H. & Adjaye, J. The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells. Stem Cells 28, 721–733 (2010).
pubmed: 20201066
doi: 10.1002/stem.404
St John, J. C. et al. The expression of mitochondrial DNA transcription factors during early cardiomyocyte in vitro differentiation from human embryonic stem cells. Cloning Stem Cells 7, 141–153 (2005).
pubmed: 16176124
doi: 10.1089/clo.2005.7.141
Zhang, H. et al. Distinct metabolic states can support self-renewal and lipogenesis in human pluripotent stem cells under different culture conditions. Cell Rep. 16, 1536–1547 (2016).
pubmed: 27477285
pmcid: 4981511
doi: 10.1016/j.celrep.2016.06.102
TeSlaa, T. et al. α-Ketoglutarate accelerates the initial differentiation of primed human pluripotent stem cells. Cell Metab. 24, 485–493 (2016).
pubmed: 27476976
pmcid: 5023506
doi: 10.1016/j.cmet.2016.07.002
Takashima, Y. et al. Resetting transcription factor control circuitry toward ground-state pluripotency in human. Cell 162, 452–453 (2015).
pubmed: 28843285
pmcid: 5628177
doi: 10.1016/j.cell.2015.06.052
Carbognin, E., Betto, R. M., Soriano, M. E., Smith, A. G. & Martello, G. Stat3 promotes mitochondrial transcription and oxidative respiration during maintenance and induction of naive pluripotency. EMBO J. 35, 618–634 (2016).
pubmed: 26903601
pmcid: 4801951
doi: 10.15252/embj.201592629
Setoguchi, K., TeSlaa, T., Koehler, C. M. & Teitell, M. A. P53 regulates rapid apoptosis in human pluripotent stem cells. J. Mol. Biol. 428, 1465–1475 (2016).
pubmed: 26239243
doi: 10.1016/j.jmb.2015.07.019
Madden, D. T., Davila-Kruger, D., Melov, S. & Bredesen, D. E. Human embryonic stem cells express elevated levels of multiple pro-apoptotic BCL-2 family members. PLoS One 6, e28530 (2011).
pubmed: 22174832
pmcid: 3235131
doi: 10.1371/journal.pone.0028530
Yanes, O. et al. Metabolic oxidation regulates embryonic stem cell differentiation. Nat. Chem. Biol. 6, 411–417 (2010).
pubmed: 20436487
pmcid: 2873061
doi: 10.1038/nchembio.364
Muir, A., Danai, L. V. & Vander Heiden, M. G. Microenvironmental regulation of cancer cell metabolism: implications for experimental design and translational studies. Dis. Model Mech. 11, dmm035758 (2018).
pubmed: 30104199
pmcid: 6124553
doi: 10.1242/dmm.035758
Marin-Valencia, I. et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 15, 827–837 (2012).
pubmed: 22682223
pmcid: 3372870
doi: 10.1016/j.cmet.2012.05.001
Davidson, S. M. et al. Environment impacts the metabolic dependencies of ras-driven non-small cell lung cancer. Cell Metab. 23, 517–528 (2016).
pubmed: 26853747
pmcid: 4785096
doi: 10.1016/j.cmet.2016.01.007
Hensley, C. T. et al. Metabolic heterogeneity in human lung tumors. Cell 164, 681–694 (2016).
pubmed: 26853473
pmcid: 4752889
doi: 10.1016/j.cell.2015.12.034
Courtney, K. D. et al. Isotope tracing of human clear cell renal cell carcinomas demonstrates suppressed glucose oxidation In Vivo. Cell Metab. 28, 793–800.e2 (2018).
pubmed: 30146487
doi: 10.1016/j.cmet.2018.07.020
pmcid: 6221993
Tardito, S. et al. Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat. Cell Biol. 17, 1556–1568 (2015).
pubmed: 26595383
pmcid: 4663685
doi: 10.1038/ncb3272
Muir, A. et al. Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition. eLife 6, e27713 (2017).
pubmed: 28826492
pmcid: 5589418
doi: 10.7554/eLife.27713
Hui, S. et al. Glucose feeds the TCA cycle via circulating lactate. Nature 551, 115–118 (2017).
pubmed: 29045397
pmcid: 5898814
doi: 10.1038/nature24057
Faubert, B. et al. Lactate metabolism in human lung tumors. Cell 171, 358–371.e359 (2017).
pubmed: 28985563
pmcid: 5684706
doi: 10.1016/j.cell.2017.09.019
Comerford, S. A. et al. Acetate dependence of tumors. Cell 159, 1591–1602 (2014).
pubmed: 25525877
pmcid: 4272450
doi: 10.1016/j.cell.2014.11.020
Mashimo, T. et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 159, 1603–1614 (2014).
pubmed: 25525878
pmcid: 4374602
doi: 10.1016/j.cell.2014.11.025
Mayers, J. R. et al. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science 353, 1161–1165 (2016).
pubmed: 27609895
pmcid: 5245791
doi: 10.1126/science.aaf5171
Yuneva, M. O. et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 15, 157–170 (2012).
pubmed: 22326218
pmcid: 3282107
doi: 10.1016/j.cmet.2011.12.015
Zhang, J. et al. LIN28 regulates stem cell metabolism and conversion to primed pluripotency. Cell Stem Cell 19, 66–80 (2016).
pubmed: 27320042
doi: 10.1016/j.stem.2016.05.009
Shyh-Chang, N. et al. Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science 339, 222–226 (2013).
pubmed: 23118012
doi: 10.1126/science.1226603
Wang, J. et al. Dependence of mouse embryonic stem cells on threonine catabolism. Science 325, 435–439 (2009).
pubmed: 19589965
pmcid: 4373593
doi: 10.1126/science.1173288
Palm, W. & Thompson, C. B. Nutrient acquisition strategies of mammalian cells. Nature 546, 234–242 (2017).
pubmed: 28593971
pmcid: 5541675
doi: 10.1038/nature22379
Zhang, J. et al. Metabolism in pluripotent stem cells and early mammalian development. Cell Metab. 27, 332–338 (2018).
pubmed: 29414683
doi: 10.1016/j.cmet.2018.01.008
Tang, F. et al. Tracing the derivation of embryonic stem cells from the inner cell mass by single-cell RNA-Seq analysis. Cell Stem Cell 6, 468–478 (2010).
pubmed: 20452321
pmcid: 2954317
doi: 10.1016/j.stem.2010.03.015
Kaneko, K. J. Metabolism of preimplantation embryo development: a bystander or an active participant? Curr. Top. Dev. Biol. 120, 259–310 (2016).
pubmed: 27475855
doi: 10.1016/bs.ctdb.2016.04.010
Houghton, F. D., Thompson, J. G., Kennedy, C. J. & Leese, H. J. Oxygen consumption and energy metabolism of the early mouse embryo. Mol. Reprod. Dev. 44, 476–485 (1996).
pubmed: 8844690
doi: 10.1002/(SICI)1098-2795(199608)44:4<476::AID-MRD7>3.0.CO;2-I
Houghton, F. D. Energy metabolism of the inner cell mass and trophectoderm of the mouse blastocyst. Differentiation 74, 11–18 (2006).
pubmed: 16466396
doi: 10.1111/j.1432-0436.2006.00052.x
Brinster, R. L. Effect of glutathione on the development of two-cell mouse embryos in vitro. J. Reprod. Fertil. 17, 521–525 (1968).
pubmed: 5752106
doi: 10.1530/jrf.0.0170521
Cholewa, J. A. & Whitten, W. K. Development of two-cell mouse embryos in the absence of a fixed-nitrogen source. J. Reprod. Fertil. 22, 553–555 (1970).
pubmed: 5453383
doi: 10.1530/jrf.0.0220553
Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L. & Dang, C. V. MYC, metabolism, and cancer. Cancer Discov. 5, 1024–1039 (2015).
pubmed: 26382145
pmcid: 4592441
doi: 10.1158/2159-8290.CD-15-0507
Kruiswijk, F., Labuschagne, C. F. & Vousden, K. H. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat. Rev. Mol. Cell Biol. 16, 393–405 (2015).
pubmed: 26122615
doi: 10.1038/nrm4007
Scognamiglio, R. et al. Myc depletion induces a pluripotent dormant state mimicking diapause. Cell 164, 668–680 (2016).
pubmed: 26871632
pmcid: 4752822
doi: 10.1016/j.cell.2015.12.033
Bulut-Karslioglu, A. et al. Inhibition of mTOR induces a paused pluripotent state. Nature 540, 119–123 (2016).
pubmed: 27880763
pmcid: 5143278
doi: 10.1038/nature20578
Merkle, F. T. et al. Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature 545, 229–233 (2017).
pubmed: 28445466
pmcid: 5427175
doi: 10.1038/nature22312
Hanna, J. et al. Direct cell reprogramming is a stochastic process amenable to acceleration. Nature 462, 595–601 (2009).
pubmed: 19898493
pmcid: 2789972
doi: 10.1038/nature08592
Paling, N. R., Wheadon, H., Bone, H. K. & Welham, M. J. Regulation of embryonic stem cell self-renewal by phosphoinositide 3-kinase-dependent signaling. J. Biol. Chem. 279, 48063–48070 (2004).
pubmed: 15328362
doi: 10.1074/jbc.M406467200
Watanabe, S. et al. Activation of Akt signaling is sufficient to maintain pluripotency in mouse and primate embryonic stem cells. Oncogene 25, 2697–2707 (2006).
pubmed: 16407845
doi: 10.1038/sj.onc.1209307
Ying, Q. L. et al. The ground state of embryonic stem cell self-renewal. Nature 453, 519–523 (2008).
pubmed: 18497825
pmcid: 5328678
doi: 10.1038/nature06968
Reid, M. A., Dai, Z. & Locasale, J. W. The impact of cellular metabolism on chromatin dynamics and epigenetics. Nat. Cell Biol. 19, 1298–1306 (2017).
pubmed: 29058720
pmcid: 5886854
doi: 10.1038/ncb3629
Su, X., Wellen, K. E. & Rabinowitz, J. D. Metabolic control of methylation and acetylation. Curr. Opin. Chem. Biol. 30, 52–60 (2016).
pubmed: 26629854
doi: 10.1016/j.cbpa.2015.10.030
Tessarz, P. & Kouzarides, T. Histone core modifications regulating nucleosome structure and dynamics. Nat. Rev. Mol. Cell Biol. 15, 703–708 (2014).
pubmed: 25315270
doi: 10.1038/nrm3890
Sivanand, S., Viney, I. & Wellen, K. E. Spatiotemporal control of acetyl-CoA metabolism in chromatin regulation. Trends Biochem. Sci. 43, 61–74 (2018).
pubmed: 29174173
doi: 10.1016/j.tibs.2017.11.004
Wellen, K. E. et al. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324, 1076–1080 (2009).
pubmed: 19461003
pmcid: 2746744
doi: 10.1126/science.1164097
Sutendra, G. et al. A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation. Cell 158, 84–97 (2014).
pubmed: 24995980
doi: 10.1016/j.cell.2014.04.046
Sivanand, S. et al. Nuclear acetyl-CoA production by ACLY promotes homologous recombination. Mol. Cell 67, 252–265.e256 (2017).
pubmed: 28689661
pmcid: 5580398
doi: 10.1016/j.molcel.2017.06.008
Nagaraj, R. et al. Nuclear localization of mitochondrial TCA cycle enzymes as a critical step in mammalian zygotic genome activation. Cell 168, 210–223.e211 (2017).
pubmed: 28086092
pmcid: 5321559
doi: 10.1016/j.cell.2016.12.026
Lee, J. V. et al. Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation. Cell Metab. 20, 306–319 (2014).
pubmed: 24998913
pmcid: 4151270
doi: 10.1016/j.cmet.2014.06.004
Cai, L., Sutter, B. M., Li, B. & Tu, B. P. Acetyl-CoA induces cell growth and proliferation by promoting the acetylation of histones at growth genes. Mol. Cell 42, 426–437 (2011).
pubmed: 21596309
pmcid: 3109073
doi: 10.1016/j.molcel.2011.05.004
Sebastián, C. et al. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 151, 1185–1199 (2012).
pubmed: 23217706
pmcid: 3526953
doi: 10.1016/j.cell.2012.10.047
Zhong, L. et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1α. Cell 140, 280–293 (2010).
pubmed: 20141841
pmcid: 2821045
doi: 10.1016/j.cell.2009.12.041
Yang, J. et al. Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression. Sci. Rep. 7, 43864 (2017).
pubmed: 28262837
pmcid: 5338333
doi: 10.1038/srep43864
Kamphorst, J. J., Chung, M. K., Fan, J. & Rabinowitz, J. D. Quantitative analysis of acetyl-CoA production in hypoxic cancer cells reveals substantial contribution from acetate. Cancer Metab. 2, 23 (2014).
pubmed: 25671109
pmcid: 4322440
doi: 10.1186/2049-3002-2-23
Schug, Z. T. et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell 27, 57–71 (2015).
pubmed: 25584894
pmcid: 4297291
doi: 10.1016/j.ccell.2014.12.002
Bulusu, V. et al. Acetate recapturing by nuclear acetyl-CoA synthetase 2 prevents loss of histone acetylation during oxygen and serum limitation. Cell Rep. 18, 647–658 (2017).
pubmed: 28099844
pmcid: 5276806
doi: 10.1016/j.celrep.2016.12.055
Metallo, C. M. et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380–384 (2011).
pubmed: 22101433
pmcid: 3710581
doi: 10.1038/nature10602
Mullen, A. R. et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481, 385–388 (2011).
pubmed: 22101431
pmcid: 3262117
doi: 10.1038/nature10642
Wise, D. R. et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc. Natl Acad. Sci. USA 108, 19611–19616 (2011).
pubmed: 22106302
doi: 10.1073/pnas.1117773108
pmcid: 3241793
Mews, P. et al. Acetyl-CoA synthetase regulates histone acetylation and hippocampal memory. Nature 546, 381–386 (2017).
pubmed: 28562591
pmcid: 5505514
doi: 10.1038/nature22405
de Thé, H. Differentiation therapy revisited. Nat. Rev. Cancer 18, 117–127 (2018).
pubmed: 29192213
doi: 10.1038/nrc.2017.103
McBrian, M. A. et al. Histone acetylation regulates intracellular pH. Mol. Cell 49, 310–321 (2013).
pubmed: 23201122
doi: 10.1016/j.molcel.2012.10.025
Berger, S. L. The complex language of chromatin regulation during transcription. Nature 447, 407–412 (2007).
pubmed: 17522673
doi: 10.1038/nature05915
Plass, C. et al. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat. Rev. Genet. 14, 765–780 (2013).
pubmed: 24105274
doi: 10.1038/nrg3554
Feinberg, A. P. & Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301, 89–92 (1983).
doi: 10.1038/301089a0
pubmed: 6185846
Kulis, M. et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat. Genet. 44, 1236–1242 (2012).
pubmed: 23064414
doi: 10.1038/ng.2443
Ehrlich, M. & Lacey, M. DNA hypomethylation and hemimethylation in cancer. Adv. Exp. Med. Biol. 754, 31–56 (2013).
pubmed: 22956495
doi: 10.1007/978-1-4419-9967-2_2
Jäkel, C. et al. Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability. Nat. Commun. 8, 1323 (2017).
pubmed: 29109526
pmcid: 5673892
doi: 10.1038/s41467-017-01118-x
Ehrlich, M. DNA methylation in cancer: too much, but also too little. Oncogene 21, 5400–5413 (2002).
pubmed: 12154403
doi: 10.1038/sj.onc.1205651
Kulis, M. & Esteller, M. DNA methylation and cancer. Adv. Genet. 70, 27–56 (2010).
pubmed: 20920744
doi: 10.1016/B978-0-12-380866-0.60002-2
Smith, Z. D. et al. DNA methylation dynamics of the human preimplantation embryo. Nature 511, 611–615 (2014).
pubmed: 25079558
pmcid: 4178976
doi: 10.1038/nature13581
DeNicola, G. M. et al. NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat. Genet. 47, 1475–1481 (2015).
pubmed: 26482881
pmcid: 4721512
doi: 10.1038/ng.3421
Locasale, J. W. et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat. Genet. 43, 869–874 (2011).
pubmed: 21804546
pmcid: 3677549
doi: 10.1038/ng.890
Possemato, R. et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476, 346–350 (2011).
pubmed: 21760589
pmcid: 3353325
doi: 10.1038/nature10350
Maddocks, O. D. et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 493, 542–546 (2013).
pubmed: 23242140
doi: 10.1038/nature11743
Edinger, A. L. & Thompson, C. B. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell. 13, 2276–2288 (2002).
pubmed: 12134068
pmcid: 117312
doi: 10.1091/mbc.01-12-0584
Kottakis, F. et al. LKB1 loss links serine metabolism to DNA methylation and tumorigenesis. Nature 539, 390–395 (2016).
pubmed: 27799657
pmcid: 5988435
doi: 10.1038/nature20132
Maddocks, O. D., Labuschagne, C. F., Adams, P. D. & Vousden, K. H. Serine metabolism supports the methionine cycle and DNA/RNA methylation through de novo ATP synthesis in cancer cells. Mol. Cell 61, 210–221 (2016).
pubmed: 26774282
pmcid: 4728077
doi: 10.1016/j.molcel.2015.12.014
Mentch, S. J. et al. Histone methylation dynamics and gene regulation occur through the sensing of one-carbon metabolism. Cell Metab. 22, 861–873 (2015).
pubmed: 26411344
pmcid: 4635069
doi: 10.1016/j.cmet.2015.08.024
Dai, Z., Mentch, S. J., Gao, X., Nichenametla, S. N. & Locasale, J. W. Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat. Commun. 9, 1955 (2018).
pubmed: 29769529
pmcid: 5955993
doi: 10.1038/s41467-018-04426-y
Dann, S. G. et al. Reciprocal regulation of amino acid import and epigenetic state through Lat1 and EZH2. EMBO J. 34, 1773–1785 (2015).
pubmed: 25979827
pmcid: 4516430
doi: 10.15252/embj.201488166
Pikman, Y. et al. Targeting MTHFD2 in acute myeloid leukemia. J. Exp. Med. 213, 1285–1306 (2016).
pubmed: 27325891
pmcid: 4925018
doi: 10.1084/jem.20151574
Bernstein, B. E. et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125, 315–326 (2006).
pubmed: 16630819
doi: 10.1016/j.cell.2006.02.041
Shiraki, N. et al. Methionine metabolism regulates maintenance and differentiation of human pluripotent stem cells. Cell Metab. 19, 780–794 (2014).
pubmed: 24746804
doi: 10.1016/j.cmet.2014.03.017
Chory, E. J. et al. Nucleosome turnover regulates histone methylation patterns over the genome. Mol. Cell 73, 61–72.e3 (2018).
pubmed: 30472189
doi: 10.1016/j.molcel.2018.10.028
pmcid: 6510544
Losman, J. A. & Kaelin, W. G. Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 27, 836–852 (2013).
pubmed: 23630074
pmcid: 3650222
doi: 10.1101/gad.217406.113
Raffel, S. et al. BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature 551, 384–388 (2017).
pubmed: 29144447
doi: 10.1038/nature24294
Knowles, H. J., Raval, R. R., Harris, A. L. & Ratcliffe, P. J. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res. 63, 1764–1768 (2003).
pubmed: 12702559
Agathocleous, M. et al. Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. Nature 549, 476–481 (2017).
pubmed: 28825709
pmcid: 5910063
doi: 10.1038/nature23876
Cimmino, L. et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell 170, 1079–1095.e1020 (2017).
pubmed: 28823558
pmcid: 5755977
doi: 10.1016/j.cell.2017.07.032
Pan, M. et al. Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation. Nat. Cell Biol. 18, 1090–1101 (2016).
pubmed: 27617932
pmcid: 5536113
doi: 10.1038/ncb3410
Hwang, I. Y. et al. Psat1-dependent fluctuations in α-ketoglutarate affect the timing of ESC differentiation. Cell Metab. 24, 494–501 (2016).
pubmed: 27476977
doi: 10.1016/j.cmet.2016.06.014
Zhu, Z. et al. PHB associates with the HIRA complex to control an epigenetic-metabolic circuit in human ESCs. Cell Stem Cell 20, 274–289.e277 (2017).
pubmed: 27939217
doi: 10.1016/j.stem.2016.11.002
Cimmino, L., Neel, B. G. & Aifantis, I. Vitamin C in stem cell reprogramming and cancer. Trends Cell Biol. 28, 698–708 (2018).
pubmed: 29724526
doi: 10.1016/j.tcb.2018.04.001
pmcid: 6102081
Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744 (2009).
pubmed: 19935646
pmcid: 2818760
doi: 10.1038/nature08617
Ward, P. S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225–234 (2010).
pubmed: 20171147
pmcid: 2849316
doi: 10.1016/j.ccr.2010.01.020
Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17–30 (2011).
pubmed: 21251613
pmcid: 3229304
doi: 10.1016/j.ccr.2010.12.014
Chowdhury, R. et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 12, 463–469 (2011).
pubmed: 21460794
pmcid: 3090014
doi: 10.1038/embor.2011.43
Koivunen, P. et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483, 484–488 (2012).
pubmed: 22343896
pmcid: 3656605
doi: 10.1038/nature10898
Losman, J. A. et al. 2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339, 1621–1625 (2013).
pubmed: 23393090
doi: 10.1126/science.1231677
Lu, C. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474–478 (2012).
pubmed: 22343901
pmcid: 3478770
doi: 10.1038/nature10860
Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553–567 (2010).
pubmed: 21130701
pmcid: 4105845
doi: 10.1016/j.ccr.2010.11.015
Saha, S. K. et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature 513, 110–114 (2014).
pubmed: 25043045
pmcid: 4499230
doi: 10.1038/nature13441
Sasaki, M. et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488, 656–659 (2012).
pubmed: 22763442
pmcid: 4005896
doi: 10.1038/nature11323
Amatangelo, M. D. et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood 130, 732–741 (2017).
pubmed: 28588019
pmcid: 5553578
doi: 10.1182/blood-2017-04-779447
Chen, C. et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev. 27, 1974–1985 (2013).
pubmed: 24065765
pmcid: 3792474
doi: 10.1101/gad.226613.113
Fan, J. et al. Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate. ACS Chem. Biol. 10, 510–516 (2015).
pubmed: 25406093
doi: 10.1021/cb500683c
Intlekofer, A. M. et al. Hypoxia induces production of L-2-hydroxyglutarate. Cell Metab. 22, 304–311 (2015).
pubmed: 26212717
pmcid: 4527873
doi: 10.1016/j.cmet.2015.06.023
Ye, D., Guan, K. L. & Xiong, Y. Metabolism, activity, and targeting of D- and L-2-hydroxyglutarates. Trends Cancer 4, 151–165 (2018).
pubmed: 29458964
pmcid: 5884165
doi: 10.1016/j.trecan.2017.12.005
Kaelin, W. G. Jr & McKnight, S. L. Influence of metabolism on epigenetics and disease. Cell 153, 56–69 (2013).
pubmed: 23540690
pmcid: 3775362
doi: 10.1016/j.cell.2013.03.004
Gottlieb, E. & Tomlinson, I. P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat. Rev. Cancer 5, 857–866 (2005).
pubmed: 16327764
doi: 10.1038/nrc1737
Selak, M. A. et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 7, 77–85 (2005).
pubmed: 15652751
doi: 10.1016/j.ccr.2004.11.022
Isaacs, J. S. et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell. 8, 143–153 (2005).
pubmed: 16098467
doi: 10.1016/j.ccr.2005.06.017
Xiao, M. et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 26, 1326–1338 (2012).
pubmed: 22677546
pmcid: 3387660
doi: 10.1101/gad.191056.112
Killian, J. K. et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 3, 648–657 (2013).
pubmed: 23550148
pmcid: 4135374
doi: 10.1158/2159-8290.CD-13-0092
Sciacovelli, M. et al. Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Nature 537, 544–547 (2016).
pubmed: 27580029
pmcid: 5136292
doi: 10.1038/nature19353
MacKenzie, E. D. et al. Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol. Cell. Biol. 27, 3282–3289 (2007).
pubmed: 17325041
pmcid: 1899954
doi: 10.1128/MCB.01927-06
Erez, A. & DeBerardinis, R. J. Metabolic dysregulation in monogenic disorders and cancer: finding method in madness. Nat. Rev. Cancer 15, 440–448 (2015).
pubmed: 26084394
doi: 10.1038/nrc3949
Kranendijk, M., Struys, E. A., Salomons, G. S., Van der Knaap, M. S. & Jakobs, C. Progress in understanding 2-hydroxyglutaric acidurias. J. Inherit. Metab. Dis. 35, 571–587 (2012).
pubmed: 22391998
pmcid: 3388262
doi: 10.1007/s10545-012-9462-5
Ma, S. et al. L2hgdh Deficiency accumulates l-2-hydroxyglutarate with progressive leukoencephalopathy and neurodegeneration. Mol. Cell Biol. 37, e00492–16 (2017).
pubmed: 28137912
pmcid: 5376639
doi: 10.1128/MCB.00492-16
Rzem, R. et al. A mouse model of L-2-hydroxyglutaric aciduria, a disorder of metabolite repair. PLoS One 10, e0119540 (2015).
pubmed: 25763823
pmcid: 4357467
doi: 10.1371/journal.pone.0119540
Kranendijk, M. et al. IDH2 mutations in patients with D-2-hydroxyglutaric aciduria. Science 330, 336 (2010).
pubmed: 20847235
doi: 10.1126/science.1192632
Akbay, E. A. et al. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev. 28, 479–490 (2014).
pubmed: 24589777
pmcid: 3950345
doi: 10.1101/gad.231233.113
Batlle, E. & Clevers, H. Cancer stem cells revisited. Nat. Med. 23, 1124–1134 (2017).
pubmed: 28985214
doi: 10.1038/nm.4409
Snyder, V., Reed-Newman, T. C., Arnold, L., Thomas, S. M. & Anant, S. Cancer stem cell metabolism and potential therapeutic targets. Front. Oncol. 8, 203 (2018).
pubmed: 29922594
pmcid: 5996058
doi: 10.3389/fonc.2018.00203
Zhou, Y. et al. Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. J. Biol. Chem. 286, 32843–32853 (2011).
pubmed: 21795717
pmcid: 3173179
doi: 10.1074/jbc.M111.260935
Chen, C. L. et al. NANOG metabolically reprograms tumor-initiating stem-like cells through tumorigenic changes in oxidative phosphorylation and fatty acid metabolism. Cell. Metab. 23, 206–219 (2016).
pubmed: 26724859
doi: 10.1016/j.cmet.2015.12.004
Li, Z. et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15, 501–513 (2009).
pubmed: 19477429
pmcid: 2693960
doi: 10.1016/j.ccr.2009.03.018
Dong, C. et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 23, 316–331 (2013).
pubmed: 23453623
pmcid: 3703516
doi: 10.1016/j.ccr.2013.01.022
Wang, Y. H. et al. Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. Cell 158, 1309–1323 (2014).
pubmed: 25215489
pmcid: 4197056
doi: 10.1016/j.cell.2014.07.048
Saito, Y., Chapple, R. H., Lin, A., Kitano, A. & Nakada, D. AMPK protects leukemia-initiating cells in myeloid leukemias from metabolic stress in the bone marrow. Cell Stem Cell 17, 585–596 (2015).
pubmed: 26440282
pmcid: 4597792
doi: 10.1016/j.stem.2015.08.019
Janiszewska, M. et al. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev. 26, 1926–1944 (2012).
pubmed: 22899010
pmcid: 3435496
doi: 10.1101/gad.188292.112
Lagadinou, E. D. et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12, 329–341 (2013).
pubmed: 23333149
pmcid: 3595363
doi: 10.1016/j.stem.2012.12.013
Sancho, P. et al. MYC/PGC-1α balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metab. 22, 590–605 (2015).
pubmed: 26365176
doi: 10.1016/j.cmet.2015.08.015
Jones, C. L. et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell 34, 724–740.e724 (2018).
pubmed: 30423294
doi: 10.1016/j.ccell.2018.10.005
pmcid: 6280965
Vlashi, E. et al. Metabolic state of glioma stem cells and nontumorigenic cells. Proc. Natl Acad. Sci. USA 108, 16062–16067 (2011).
pubmed: 21900605
doi: 10.1073/pnas.1106704108
pmcid: 3179043
Kuntz, E. M. et al. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nat. Med. 23, 1234–1240 (2017).
pubmed: 28920959
pmcid: 5657469
doi: 10.1038/nm.4399
Ye, H. et al. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell 19, 23–37 (2016).
pubmed: 27374788
pmcid: 4938766
doi: 10.1016/j.stem.2016.06.001
Pascual, G. et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature 541, 41–45 (2017).
doi: 10.1038/nature20791
pubmed: 27974793
Samudio, I. et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J. Clin. Invest. 120, 142–156 (2010).
pubmed: 20038799
doi: 10.1172/JCI38942
Li, J. et al. Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells. Cell Stem Cell 20, 303–314.e305 (2017).
pubmed: 28041894
doi: 10.1016/j.stem.2016.11.004
El Helou, R. et al. miR-600 acts as a bimodal switch that regulates breast cancer stem cell fate through WNT signaling. Cell Rep. 18, 2256–2268 (2017).
pubmed: 28249169
doi: 10.1016/j.celrep.2017.02.016